

Study Suggests Sleep Apnea Link to Alzheimer's

BY BRUCE JANCIN
Denver Bureau

DENVER — The well-documented association between the apolipoprotein E $\epsilon 4$ allele and development of cognitive decline and Alzheimer's disease may be mediated at least in part by obstructive sleep apnea, Ruth O'Hara, Ph.D., said at the annual meeting of the Associated Professional Sleep Societies.

This is an exciting possibility, because although no therapies are available to delay the onset of dementia, continuous positive airway pressure (CPAP) offers a highly effective treatment for obstructive sleep apnea. It's possible that identifying and treating this disorder in apo E $\epsilon 4$ -positive patients could delay or perhaps even prevent the onset of cognitive decline and Alzheimer's dementia, according to Dr. O'Hara of Stanford (Calif.) University.

She presented a cross-sectional study of 36 community-dwelling nondemented older adults—mean age 70 years—half of

whom possessed the apo E $\epsilon 4$ allele. All were assessed for cognitive performance status by the Mini-Mental State Examination and Rey Auditory Verbal Learning Test. The presence and severity of obstructive sleep apnea were assessed using home ventilatory polygraphy.

The most striking study finding was that although there was no difference in cognitive function between the apo E $\epsilon 4$ -positive and -negative groups overall, apo E $\epsilon 4$ -positive individuals with sleep

apnea as defined by a higher apnea/hypopnea index had lower memory scores as reflected by worse performance on the delayed recall and short-term recall components of the Rey test. The higher an apo E $\epsilon 4$ -positive subject's apnea/hypopnea index, the lower their memory scores. In contrast, the apnea/hypopnea index was unrelated to memory function in individuals who didn't carry the apo E $\epsilon 4$ allele.

Daytime sleepiness was unrelated to cognitive performance in either group.

Dr. O'Hara said that it's impossible to tell from a cross-sectional study such as this whether sleep apnea is mediating the effect of the apo E $\epsilon 4$ allele as a risk factor for development of cognitive decline and Alzheimer's disease. That's a question that can be addressed only in a longitudinal study. On the strength of the provocative cross-sectional study findings, the National Institute of Mental Health has granted funding for Dr. O'Hara and coworkers to conduct a 150-subject prospective study. ■

Lifestyle Factors May Affect Gene Carriers' AD Risk

STOCKHOLM — Individuals who carry the apolipoprotein E $\epsilon 4$ allele that increases the risk of developing Alzheimer's disease may lower their risk to that of a noncarrier through regular exercise, moderate fat intake, and low alcohol consumption, reported Tiia Ngandu at the 12th Congress of the International Psychogeriatric Association.

Ms. Ngandu and her associates studied 1,449 Finnish people who participated in the longitudinal, population-based Cardiovascular Risk Factors, Aging, and Dementia study (CAIDE) in 1972, 1977, 1982, or 1987. After an average follow-up of 21 years, the participants were aged 65-79 years when they were re-examined in 1998.

Based on questions answered at midlife, active individuals (exercised at least twice per week) who carried the $\epsilon 4$ allele had a significantly lower likelihood of developing Alzheimer's disease (AD) than sedentary carriers, said Ms. Ngandu, a doctoral student at the Aging Research Center at the Karolinska Institute, Stockholm.

Intake of polyunsaturated fatty acids did not alter the odds of developing AD in carriers, but high intake of saturated fatty acids was associated with significantly greater odds of AD in carriers, compared with a low intake.

Carriers who frequently consumed alcohol had a significantly higher likelihood of developing AD than carriers who drank infrequently or never.

None of the lifestyle factors reduced the risk of AD in noncarriers, she noted.

People with a parent with late-onset Alzheimer's disease may undergo genotyping for apolipoprotein E. A positive finding is not diagnostic of Alzheimer's disease, even in a symptomatic patient.

—Jeff Evans

Change is in the Air

Introducing ATROVENT® HFA:

The same medication, now in a different formulation

- ATROVENT® (ipratropium bromide) Inhalation Aerosol (CFC) will not be available after December 2005
- ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol has demonstrated comparable safety and efficacy to the CFC formulation
- Re-evaluate your patients on ATROVENT® Inhalation Aerosol (CFC) at their next office visit and consider the benefits of switching to SPIRIVA® HandiHaler®
- For patients switching from ATROVENT® Inhalation Aerosol (CFC) to ATROVENT® HFA, a new prescription specifying "ATROVENT® HFA" will be necessary
- ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, but is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response
- ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other ATROVENT® HFA Inhalation Aerosol components. Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis and oropharyngeal edema. ATROVENT® HFA Inhalation Aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives
- Inhaled medicines, including ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol, may cause paradoxical bronchospasm. If this occurs, treatment with ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol should be stopped and other treatments considered
- ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction. Patients should avoid spraying the aerosol into their eyes. This may result in precipitation or worsening of narrow-angle glaucoma, mydriasis, eye pain or discomfort, temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion. Should any combination of these symptoms develop, patients should consult their physician immediately
- The most common drug-related adverse events were dry mouth (1.6% of ATROVENT® HFA Inhalation Aerosol and 0.9% of ATROVENT® Inhalation Aerosol CFC patients), and taste perversion (bitter taste) (0.9% of ATROVENT® HFA Inhalation Aerosol and 0.3% of ATROVENT® Inhalation Aerosol CFC patients)
- SPIRIVA HandiHaler is intended as a once-daily maintenance treatment for COPD and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e., rescue therapy. SPIRIVA HandiHaler is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, i.e., ipratropium or to any component of this product. The most commonly reported adverse drug reaction was dry mouth, which was usually mild and often resolved during continued treatment. Other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurred vision, glaucoma, urinary difficulty and urinary retention. Inhaled medicines, including SPIRIVA, may cause paradoxical bronchospasm. If this occurs, treatment with SPIRIVA should be stopped and other treatments considered

Please see Brief Summary of Prescribing Information for ATROVENT® HFA Inhalation Aerosol and SPIRIVA® HandiHaler® on pages following this advertisement.

SPIRIVA® HandiHaler®
(tiotropium bromide inhalation powder)

ATROVENT® HFA
(ipratropium bromide HFA)
INHALATION AEROSOL 17 mcg per puff



Copyright © 2005, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.

Printed in U.S.A.

(6/05)

AT-10286